Skip to main content
SpringerLink
Log in

Systemic Antifungals

  • Chapter
Infection Control in the Intensive Care Unit

Part of the book series: Topics in Anaesthesia and Critical Care ((TIACC))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beck-Sague CM, Jarvis WR, and the National Nosocomial Infections Surveillance System (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980–1990. J Infect Dis 167: 1247–1251

    PubMed  CAS  Google Scholar 

  2. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887–892

    Article  PubMed  CAS  Google Scholar 

  3. Trick WE, Fridkin SK, Edwards JR et al (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630

    Article  PubMed  CAS  Google Scholar 

  4. Pfaller MA, Diekema DJ (2002) Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40:3551–3557

    Article  PubMed  CAS  Google Scholar 

  5. Edmond MB, Wallace SE, McClish DK et al (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244

    PubMed  CAS  Google Scholar 

  6. Blumberg HM, Jarvis WR, Soucie JM et al (2001) Risk factors for Candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177–186

    Article  PubMed  CAS  Google Scholar 

  7. Saiman L, Ludington E, Pfaller M (2000) Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 19:319–324

    Article  PubMed  CAS  Google Scholar 

  8. Pfaller MA, Diekema DJ, Jones RN et al (2001) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 39:3254–3259

    Article  PubMed  CAS  Google Scholar 

  9. Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49[Suppl 1]:7–10

    PubMed  CAS  Google Scholar 

  10. Dupont B (2002) Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49[Suppl 1]:31–36

    PubMed  CAS  Google Scholar 

  11. Steinbach WJ, Perfect JR (2003) Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 7:5–20

    Article  PubMed  Google Scholar 

  12. Eriiksson U, Seifert B, Schaffner A (2001) Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322:579–582

    Article  Google Scholar 

  13. Wingard JR (2002) Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 35:891–895

    Article  PubMed  CAS  Google Scholar 

  14. Richardson MD, Warnock DW (2003) Fungal infection: diagnosis and management. Antifungal drugs. Blackwell, Massachusetts, pp 29–79

    Google Scholar 

  15. Rogers TR (2001) Optimal use of existing and new antifungal drugs. Curr Opin Crit Care 7:238–241

    Article  PubMed  CAS  Google Scholar 

  16. Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad spectrum antibacterial therapy. Ann Intern Med 135:412–422

    PubMed  CAS  Google Scholar 

  17. Slain D, Rogers DP, Cleary JD, Chapman SW (2001) Intravenous itraconazole. Ann Pharmacother 35: 720–729

    Article  PubMed  CAS  Google Scholar 

  18. Winston DJ, Maziarz RT, Pranatharthi H et al (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 138:705–713

    PubMed  CAS  Google Scholar 

  19. Caillot D, Bassaris H, McGeer A (2001) Intravenous itraconazole by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33:e83–90

    Article  PubMed  CAS  Google Scholar 

  20. Johnson LB, Kaufmann CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630–637

    Article  PubMed  CAS  Google Scholar 

  21. Gothard P, Rogers TR (2004). Voriconazole for serious fungal infections. Int J Clin Pract 54:74–80

    Article  Google Scholar 

  22. Herbrecht R, Denning DW, Patterson TF et al ( 2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  PubMed  CAS  Google Scholar 

  23. Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  PubMed  CAS  Google Scholar 

  24. Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    Article  PubMed  CAS  Google Scholar 

  25. Ally R, Scharmann D, Kreisel W et al (2001) A randomized, double blind, double dummy,multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447–1454

    Article  PubMed  CAS  Google Scholar 

  26. Adis International Ltd (2003) Posaconazole:SCH56592. Drugs: 258–263

    Google Scholar 

  27. Pfaller MA, Messer SA, Hollis RJ et al (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032–1037

    Article  PubMed  CAS  Google Scholar 

  28. Hachem RY, Raad II, Afif CM et al (2000) An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory(R) to or intolerant(I) to standard therapy(ST). Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, p 372, abs no. 1109

    Google Scholar 

  29. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF (2002) Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 49:353–357

    Article  PubMed  CAS  Google Scholar 

  30. Francis P, Walsh TJ (1992) Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 15:1003–1018

    PubMed  CAS  Google Scholar 

  31. Denning DW (2002) Echinocandins: a new class of antifungal. J Antimicrob Chemother 49:889–893

    Article  PubMed  CAS  Google Scholar 

  32. Anonymous (2004) Caspofungin and voriconazole for fungal infections. Drugs Ther Bull 42:5–8

    Article  Google Scholar 

  33. Deresinski SC, Stevens DA (2003) Caspofungin. Clin Infect Dis 36:1445–1457

    Article  PubMed  CAS  Google Scholar 

  34. Keating GM, Jarvis B (2001) Caspofungin. Drugs 61:1121–1129

    Article  PubMed  CAS  Google Scholar 

  35. Villanueva A, Arathoon EG, Gotuzzo E et al (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529–1535

    Article  PubMed  CAS  Google Scholar 

  36. Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029

    Article  PubMed  CAS  Google Scholar 

  37. Maertens et al (2002) Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: an analysis of 90 patients. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy California September 27-30.

    Google Scholar 

  38. Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402

    Article  PubMed  CAS  Google Scholar 

  39. Ostrosky-Zeichner L, Rex JH, Pappas PG et al (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154

    Article  PubMed  CAS  Google Scholar 

  40. Krause DS, Reinhardt J, Vazquez JA et al (2004) Phase 2, randomised, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48: 2021–2024

    Article  PubMed  CAS  Google Scholar 

  41. Odds FC, Brown AJ, Gow NA (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11: 272–279

    Article  PubMed  CAS  Google Scholar 

  42. Rogers TR (2002) Antifungal drug resistance: does it matter? Int J Infect Dis 6[Suppl 1]:S47–S53

    Article  PubMed  Google Scholar 

  43. Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–517

    PubMed  CAS  Google Scholar 

  44. Kontoyiannis DP, Lewis RE (2004) Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 126:165–175

    Article  PubMed  CAS  Google Scholar 

  45. Matthews RC, Burnie JP (2004) Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22:865–871

    Article  PubMed  CAS  Google Scholar 

  46. Rex JH, Sobel JD (2001) Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 32:1191–1200

    Article  PubMed  CAS  Google Scholar 

  47. Rex JH, Walsh TJ, Sobel JD et al (2000) Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30:662–678

    Article  PubMed  CAS  Google Scholar 

  48. Neely MN, Schreiber JR (2001) Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics 107:404–405

    Article  PubMed  CAS  Google Scholar 

  49. Rex JH, Pappas PG, Karchmen AW et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 36:1221–1228

    Article  PubMed  CAS  Google Scholar 

  50. Gottfredsson M, Perfect JR (1999) Use of antifungal agents in the intensive care unit. Curr Opin Crit Care 5:381–390

    Article  Google Scholar 

  51. Perfect JR, Marr KA, Walsh TJ et al (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122–1131

    Article  PubMed  CAS  Google Scholar 

  52. Steinbach WJ, Stevens DA (2003) Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37[Suppl 3]:S157–S187

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Microbiology, Hammersmith Hospital, London, UK

    F. J. Cooke

  2. Department of Clinical Microbiology, Trinity Centre, Dublin, Ireland

    T. Rogers

Authors
  1. F. J. Cooke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Microbiology, University of Liverpool Alder Hey Children’s Hospital, NHS Trust, Liverpool, UK

    H. K. F. van Saene M.D.

  2. Department of Critical Care Medicine, University Hospital of Getafe, Madrid, Spain

    M. A. De La Cal M.D.

  3. Emergency Department and Unit of Anesthesia and Intensive Care, Presidio Ospedaliero of Gorizia, Gorizia, Italy

    L. Silvestri M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Italia

About this chapter

Cite this chapter

Cooke, F.J., Rogers, T. (2005). Systemic Antifungals. In: van Saene, H.K.F., De La Cal, M.A., Silvestri, L. (eds) Infection Control in the Intensive Care Unit. Topics in Anaesthesia and Critical Care. Springer, Milano . https://doi.org/10.1007/88-470-0361-X_8

Download citation

  • DOI: https://doi.org/10.1007/88-470-0361-X_8

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0185-5

  • Online ISBN: 978-88-470-0361-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation